NASDAQ · Biotechnology

Gain Therapeutics, Inc. (GANX) Stock

$1.60 -2.74% NASDAQ: GANX Healthcare

Valuation

MetricValue
Price$1.60
Market Cap$68.03M
P/E Ratio-3.64
P/B Ratio6.91
P/S Ratio0.00
EPS (TTM)$-0.61
52-Week High$4.34
52-Week Low$1.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-161.58%
ROA-130.37%
ROCE-95.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio7.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-18.0M$-22.0M$-20.0M$-19.0M
Net Profit$-14.0M$-18.0M$-22.0M$-20.0M$-20.0M
EPS$-1.37$-1.48$-1.71$-0.89$-0.61
Op Margin-8379.8%-12688.1%-40328.3%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$39.0M$24.0M$19.0M$12.0M$23.0M
Total Liabilities$4.0M$5.0M$6.0M$5.0M$4.0M
Cash$37.0M$7.0M$12.0M$10.0M$21.0M
Borrowings$2.0M$1.0M$1.0M$1.0M$1.0M

Latest News

Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO MT Newswires · Jul 16, 2026 Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update GlobeNewswire · Jul 16, 2026 Why Is GANX Stock Rallying 22% After Hours? Stocktwits · Jun 29, 2026 Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease MT Newswires · Jun 29, 2026 Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease GlobeNewswire · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-15.0M$-19.0M$-19.0M$-18.0M
Investing Cash Flow$0$-15.0M$10.0M$5.0M$0
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$29.0M$-30.0M$4.0M$-1.0M$10.0M
Free Cash Flow$-12.0M$-15.0M$-19.0M$-19.0M$-18.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.13
EV / EBITDA-3.41
FCF Yield-24.68%
Quick Ratio7.33
Interest Coverage0.00
Return 1Y-2.65%
Return 3Y-62.73%
Return 5Y-82.51%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACETAdicet Bio, Inc. $5.60 -0.25% -0.57 $52.31M 0.00%
ADAGAdagene Inc. $3.67 +1.66% -7.78 $138.17M 0.00%
CRVOCervoMed Inc. $3.22 -1.83% -0.94 $29.81M 0.00%
FBIOFortress Biotech, Inc. $2.11 -1.17% 0.64 $70.09M 0.00%
LITSLite Strategy, Inc. $1.22 -3.93% -0.15 $41.51M 0.00%

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is led by CEO Gene Mack, employs 23 people, headquartered in US, publicly traded since 2021.

Gain Therapeutics, Inc. (GANX) stock trades at $1.60 with a market capitalization of $68.03M. The stock is valued at a price-to-earnings (P/E) ratio of -3.64, price-to-book of 6.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.53 and $4.34, and currently trades 63.1% below its 52-week high.

On profitability, Gain Therapeutics, Inc. generates a return on equity (ROE) of -161.58%, return on capital employed of -95.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1182.62 +0.28% JNJ Johnson & Johnson $263.73 +0.88% ABBV AbbVie Inc. $281.04 +1.65% MRK Merck & Company, Inc. Common Stock (new) $145.45 -0.10% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.52 -0.21% NVS Novartis AG $143.84 +0.06% AZN AstraZeneca PLC $158.58 -0.39% TMO Thermo Fisher Scientific Inc $662.24 +0.64% AMGN Amgen Inc. $417.57 +0.65% GILD Gilead Sciences, Inc. $150.43 -0.49% ABT Abbott Laboratories $101.82 +2.23% NVO Novo Nordisk A/S $38.64 +0.00%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides